Novo Nordisk (NVO) Stock Price Prediction: Rally tests resistance after Novo raises outlook and Binance flows lean long

Outlook upgrade is the main fundamental driver

Novo Nordisk raised its 2026 outlook for the third time this year on November 4, 2026 after Wegovy pill sales exceeded forecasts, according to Reuters. That is the cleanest fundamental takeaway in the package: management has shown enough confidence to lift guidance again, but the market is still being asked to separate genuine operating momentum from one-time help in the numbers.

Jefferies, via Michael Leuchten, kept a Hold rating on November 4 and said the upgraded outlook could support higher analyst forecasts. But the firm also flagged that a DKK2 billion pricing benefit helped the sales beat; without it, injectable Wegovy would have missed consensus expectations. That matters because it tempers the quality of the beat and keeps expectations from running too far ahead of the underlying trend.

Binance Futures is constructive, but not stretched

On Binance Futures, NVO last traded at $41.29, up 2.13% on the day, inside a 24-hour range of $39.79 to $41.49. The move leaves price just under the upper Bollinger Band at $41.58 and above the 7-, 20- and 50-day moving averages, which is a short-term bullish structure, but not an extended one.

Momentum is mixed rather than euphoric. RSI at 59.64 sits in neutral territory, while the MACD histogram is flat at 0.0000, which points to momentum that is positive on price structure but not yet accelerating. ATR at $1.17 says the name can still move quickly enough to matter intraday.

What the derivatives tape is saying

The derivatives data leans long without looking crowded. Global accounts are 68.7% long versus 31.3% short, and top-trader accounts are even more tilted at 73.4% long versus 26.7% short, both measured at 2026-11-09 12:00:00 UTC. Funding is neutral at 0.0000%, so the market is not showing an obvious cost to hold longs, and open interest is up 0.68% over 24 hours to 23,323.49 contracts, with open interest value at $941,471.

That combination usually means traders are leaning with the move, but not paying a premium to do it. The order flow is also balanced: taker buy/sell ratio is 1.0731, with buy volume 539 versus sell volume 503. In plain terms, buyers have a slight edge, but there is no sign of a one-way blowoff.

Levels that matter from here

The first technical test is immediate resistance at $41.92, followed by stronger resistance at $42.56. On the downside, immediate support sits at $40.22 and stronger support at $39.16, with the pivot at $40.86.

Because spot is already near the upper Bollinger Band and below immediate resistance, the tape is vulnerable to a pause or a shallow pullback if buyers fail to clear $41.92 cleanly. A decisive push through $41.92 would leave $42.56 as the next obvious checkpoint. A loss of $40.22 would weaken the short-term setup and hand control back to the lower moving averages and the $39.16 support zone.

Trade framing

Scenario; Direction: long; Entry: $41.29; Stop: $40.22; Target: $42.56; Reward/risk: 1.19:1 (before fees, slippage and gaps).

The main uncertainty is whether the recent guidance upgrade and Wegovy sales strength are enough to sustain follow-through after the first burst higher. If price cannot hold above $40.22, the market is saying the reaction to the news has likely been overdone for now.